Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1
Authors
Keywords
-
Journal
CIRCULATION RESEARCH
Volume 126, Issue 4, Pages 486-500
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2019-12-20
DOI
10.1161/circresaha.119.315099
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of PI3K/Akt signaling pathway in non‐physiological shear stress‐induced platelet activation
- (2019) Zengsheng Chen et al. ARTIFICIAL ORGANS
- Effects of upstream shear forces on priming of platelets for downstream adhesion and activation
- (2018) Shekh M. Rahman et al. Acta Biomaterialia
- Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation
- (2018) Christina Ji-Young Lee et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cathelicidins prime platelets to mediate arterial thrombosis and tissue inflammation
- (2018) Joachim Pircher et al. Nature Communications
- Intracellular platelet signalling as a target for drug development
- (2018) Gemma Vilahur et al. VASCULAR PHARMACOLOGY
- Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases
- (2018) Jens J. Posma et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
- (2017) Marco Valgimigli et al. EUROPEAN HEART JOURNAL
- Inflammatory cell content of coronary thrombi is dependent on thrombus age in patients with ST-elevation myocardial infarction
- (2017) Wessel W. Fuijkschot et al. Journal of Cardiology
- Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation
- (2017) A. Achilles et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation
- (2017) B. Steppich et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- (2017) John W. Eikelboom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Do methodological differences account for the current controversy on tissue factor expression in platelets?
- (2017) Marta Brambilla et al. PLATELETS
- Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding
- (2017) Pancras C. Wong et al. Science Translational Medicine
- Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
- (2017) José A López-López et al. BMJ-British Medical Journal
- Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
- (2017) José A López-López et al. BMJ-British Medical Journal
- Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome
- (2017) Bahar Artim-Esen et al. Scientific Reports
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
- (2016) Paulus Kirchhof et al. EUROPEAN HEART JOURNAL
- The Perseus computational platform for comprehensive analysis of (prote)omics data
- (2016) Stefka Tyanova et al. NATURE METHODS
- Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding
- (2016) Pasquale Pignatelli et al. PHARMACOLOGICAL RESEARCH
- Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis
- (2016) T. Petzold et al. Science Translational Medicine
- Effects of Rivaroxaban on Platelet Activation and Platelet–Coagulation Pathway Interaction
- (2015) Elisabeth Perzborn et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Spatiotemporal regulation of coagulation and platelet activation during the hemostatic responsein vivo
- (2015) L. Ivanciu et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers
- (2015) Noa Zemer-Wassercug et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair
- (2015) H. B. Schiller et al. Molecular Systems Biology
- Network Meta-Analysis of Oral Anticoagulants for Primary Prevention, Treatment and Secondary Prevention of Venous Thromboembolic Disease, and for Prevention of Stroke in Atrial Fibrillation
- (2015) JA Lopez-Lopez et al. VALUE IN HEALTH
- Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
- (2015) G. Magnani et al. Journal of the American Heart Association
- New insights into the spatiotemporal localization of prothrombinase in vivo
- (2014) L. Ivanciu et al. BLOOD
- A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel
- (2014) Mark R. Thomas et al. PLATELETS
- Biased Signaling of Protease-Activated Receptors
- (2014) Peishen Zhao et al. Frontiers in Endocrinology
- Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors
- (2013) Ramin Artang et al. AMERICAN JOURNAL OF CARDIOLOGY
- Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
- (2013) Wolfgang Mueck et al. CLINICAL PHARMACOKINETICS
- Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial
- (2013) Kenneth W. Mahaffey et al. EUROPEAN HEART JOURNAL
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation
- (2013) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hydrogen Sulfide–Releasing Aspirin Derivative ACS14 Exerts Strong Antithrombotic Effects In Vitro and In Vivo
- (2012) Joachim Pircher et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Vorapaxar in the Secondary Prevention of Atherothrombotic Events
- (2012) David A. Morrow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the Factor Xa Inhibitor Rivaroxaban on Arterial Thrombosis in Wild-Type and Apolipoprotein E-Deficient Mice
- (2012) Nana-Maria Wagner et al. THROMBOSIS RESEARCH
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
- (2011) Jessica L. Mega et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
- (2011) Pierluigi Tricoci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platelet Matrix Metalloprotease-1 Mediates Thrombogenesis by Activating PAR1 at a Cryptic Ligand Site
- (2009) Vishal Trivedi et al. CELL
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search